XPO1 and cancer: Considering these findings, Crm1 has emerged over the years as a therapeutic target for anticancer therapy, using functional analogs of the Crm1 inhibitor, Leptomycin B (LMB; Green et al., 2015; Parikh et al., 2014; Walker et al., 2013; Zhong et al., 2014); thus, successful characterization of LMB-mediated nucleocytoplasmic redistribution indicates potential utility of the method in a variety of cancer-related studies.